

# JC virus reactivation during prolonged natalizumab mo

Annals of Neurology

75, 925-934

DOI: [10.1002/ana.24148](https://doi.org/10.1002/ana.24148)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New and Old Concepts and Strategies for Progressive Multifocal Leukoencephalopathy. Journal of Multiple Sclerosis, 2014, 02, .	0.1	0
2	Relevance of CD34+ Cells as a Reservoir for JC Virus in Patients With Multiple Sclerosis. JAMA Neurology, 2014, 71, 1192.	4.5	2
3	Viral infections in mice with reconstituted human immune system components. Immunology Letters, 2014, 161, 118-124.	1.1	6
4	Lack of Major Histocompatibility Complex Class I Upregulation and Restrictive Infection by JC Virus Hamper Detection of Neurons by T Lymphocytes in the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2015, 74, 791-803.	0.9	9
5	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 357-361.	0.9	1
6	Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors. Frontiers in Immunology, 2015, 6, 159.	2.2	38
7	Hematopoietic mobilization. Neurology, 2015, 84, 1473-1482.	1.5	27
8	Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab. Journal of Neuroimmunology, 2015, 287, 76-79.	1.1	26
9	Persistence and pathogenesis of the neurotropic polyomavirus <scp>JC</scp>. Annals of Neurology, 2015, 77, 560-570.	2.8	113
10	Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients. Molecular and Cellular Probes, 2015, 29, 54-62.	0.9	13
11	Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab. Frontiers in Immunology, 2014, 5, 668.	2.2	27
12	Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohnâ€™s Disease and Effects of Natalizumab Therapy. Clinical Gastroenterology and Hepatology, 2015, 13, 1919-1925.	2.4	21
13	Immunology of progressive multifocal leukoencephalopathy. Journal of NeuroVirology, 2015, 21, 614-622.	1.0	36
14	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Multiple Sclerosis Journal, 2015, 21, 1036-1044.	1.4	78
15	JC virus reactivation in patients with autoimmune rheumatic diseases treated with rituximab. Scandinavian Journal of Rheumatology, 2016, 45, 507-511.	0.6	5
16	Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals. Current Infectious Disease Reports, 2016, 18, 33.	1.3	13
17	Effetti collaterali delle bioterapie nella sclerosi multipla e nelle malattie correlate. EMC - Neurologia, 2016, 16, 1-10.	0.0	0
18	Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. European Journal of Neurology, 2016, 23, 182-189.	1.7	11

#	ARTICLE	IF	CITATIONS
19	Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature. <i>Clinical Infectious Diseases</i> , 2016, 62, 986-994.	2.9	59
20	Natalizumab in relapsing-remitting multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 471-481.	1.4	8
21	Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. <i>Neurotherapeutics</i> , 2016, 13, 163-178.	2.1	17
22	Progressive multi-focal leucoencephalopathy “ driven from rarity to clinical mainstream by iatrogenic immunodeficiency. <i>Clinical and Experimental Immunology</i> , 2017, 188, 342-352.	1.1	20
23	Protective Humoral Immunity in the Central Nervous System Requires Peripheral CD19-Dependent Germinal Center Formation following Coronavirus Encephalomyelitis. <i>Journal of Virology</i> , 2017, 91, .	1.5	8
24	JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab. <i>Journal of NeuroVirology</i> , 2017, 23, 226-238.	1.0	7
25	Cerebellar Involvement in an Immunocompetent Patient Presenting with Progressive Multifocal Leukoencephalopathy. <i>Case Reports in Neurological Medicine</i> , 2017, 2017, 1-3.	0.3	4
26	T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. <i>Immunobiology</i> , 2018, 223, 508-517.	0.8	31
27	Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. <i>Lancet Neurology</i> , The, 2018, 17, 467-480.	4.9	147
28	Detection and analysis of variants of JC polyomavirus in urine samples from HIV-1-infected patients in China’s Zhejiang Province. <i>Journal of International Medical Research</i> , 2018, 46, 1024-1032.	0.4	8
29	Effector T Cells in Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a029025.	2.9	192
30	Signaling pathways and therapeutic perspectives related to environmental factors associated with multiple sclerosis. <i>Journal of Neuroscience Research</i> , 2018, 96, 1831-1846.	1.3	8
31	Frontline Science: Buprenorphine decreases CCL2-mediated migration of CD14+CD16+monocytes. <i>Journal of Leukocyte Biology</i> , 2018, 104, 1049-1059.	1.5	23
32	Slowly progressive fatal PML-IRIS following antiretroviral initiation at CD4+ nadir of 350 cells/mm <sup>3</sup> despite CD4+ cell count rise to 900 cells/mm <sup>3</sup> . <i>International Journal of STD and AIDS</i> , 2019, 30, 810-813.	0.5	0
33	JC virus infection of meningeal and choroid plexus cells in patients with progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2019, 25, 520-524.	1.0	14
34	Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2020, 26, 133-137.	1.0	2
35	Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. <i>Frontiers in Immunology</i> , 2020, 11, 549842.	2.2	52
36	The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1297-1300.	1.4	0

#	ARTICLE	IF	CITATIONS
37	The Role of the JC Virus in Central Nervous System Tumorigenesis. International Journal of Molecular Sciences, 2020, 21, 6236.	1.8	22
38	Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nature Reviews Neurology, 2021, 17, 37-51.	4.9	173
39	Understanding polyomavirus CNS disease – a perspective from mouse models. FEBS Journal, 2022, 289, 5744-5761.	2.2	5
40	Lesson for the clinical nephrologist: immune monitoring of human JC-polyomavirus in kidney transplantation. Journal of Nephrology, 2021, , 1.	0.9	1
41	Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab. Multiple Sclerosis and Related Disorders, 2021, 56, 103266.	0.9	1
42	Novel Treatment. , 2016, , 283-292.		0